GetTopicDetailResponse(id=e7241251448f, topicName=伊那利塞, introduction=, content=乳腺癌 氟維司群 哌柏西利 伊那利塞, image=null, comments=0, allHits=366, url=null, type=0, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Sun Mar 16 12:45:42 CST 2025, time=2025-03-16, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=502551, tagList=[TagDto(tagId=502551, tagName=伊那利塞)], ipAttribution=上海, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2256297, encodeId=fe08225629e75, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=553b639416e' target=_blank style='color:#2F92EE;'>#氟維司群#</a> <a href='/topic/show?id=46043990410' target=_blank style='color:#2F92EE;'>#哌柏西利#</a> <a href='/topic/show?id=e7241251448f' target=_blank style='color:#2F92EE;'>#伊那利塞#</a>, objectTitle=國(guó)內(nèi)首個(gè)批準(zhǔn)羅氏PI3Kα抑制劑伊那利塞片上市！用于治療PIK3CA突變、HR+/HER2-乳腺癌！, objectType=article, longId=867505, objectId=6ffd86e50597, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20250227/ca695b1b8acc42fca5156d6084e84d07-u7oA6t2PYz8s.jpg, objectUrl=/article/show_article.do?id=6ffd86e50597, replyNumber=0, likeNumber=46, createdTime=2025-03-16, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=6ffd86e50597, moduleTitle=國(guó)內(nèi)首個(gè)批準(zhǔn)羅氏PI3Kα抑制劑伊那利塞片上市！用于治療PIK3CA突變、HR+/HER2-乳腺癌！, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=6ffd86e50597)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2025-03-16發(fā)表于上海
